• R M Ahmed, R W Paterson, J D Warren, H Zetterberg, J T O'Brien, N C Fox, G M Halliday, and J M Schott.
• Neuroscience Research Australia and the University of NSW, Sydney, New South Wales, Australia.
• J. Neurol. Neurosurg. Psychiatr. 2014 Dec 1; 85 (12): 142614341426-34.

AbstractImaging, cerebrospinal fluid (CSF) and blood-based biomarkers have the potential to improve the accuracy by which specific causes of dementia can be diagnosed in vivo, provide insights into the underlying pathophysiology, and may be used as inclusion criteria and outcome measures for clinical trials. While a number of imaging and CSF biomarkers are currently used for each of these purposes, this is an evolving field, with numerous potential biomarkers in varying stages of research and development. We review the currently available biomarkers for the three most common forms of neurodegenerative dementia, and give an overview of research techniques that may in due course make their way into the clinic.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

23 keywords...

hide…